13D Filing: Eses Holdings and Adamis Pharmaceuticals Corp (ADMP)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 9)*

ADAMIS
PHARMACEUTICALS CORPORATION

Name of Issuer

COMMON
STOCK, $0.0001 Par Value

(Title of Class of Securities)

00547W208

(CUSIP Number)

Ahmed Shayan Fazlur Rahman

c/o Eses Holdings (FZE)

Sharjah Airport International Free Zone

Executive Suite, P.O. Box 9366

Sharjah, United Arab Emirates
+971-4-363-846

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 12, 2016

(Date of Event which Requires Filing of
this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies
are to be sent.

*The information required on the remainder of this cover
page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

This Amendment
No. 9 (this “Amendment No. 9”) amends and restates the Schedule 13D originally filed with the United States
Securities and Exchange Commission (the “SEC”) by Ahmed Shayan Fazlur Rahman and Eses Holdings (FZE) on November
22, 2010, and amended by Amendment No. 1 thereto filed on July 5, 2011, Amendment No. 2 thereto filed on July 26, 2011, Amendment
No. 3 thereto filed on November 21, 2011, Amendment No. 4 thereto filed on February 3, 2012, Amendment No. 5 thereto filed on July
30, 2013, Amendment No. 6 thereto filed on December 24, 2013, Amendment No. 7 thereto filed on June 16, 2014 and Amendment No.
8 thereto filed on February 17, 2015 (as so amended, the “Statement”) relating to the shares of common stock,
$0.0001 par value per share (the “Common Stock”), of Adamis Pharmaceuticals Corporation, a Delaware corporation
(the “Company”). This Amendment No. 9 reflects changes to Items 5 and 7 of the Statement.

The Reporting
Persons, as defined below, are filing this Amendment No. 9 to report the change in their beneficial ownership of Common Stock due
to an increase in the number of Common Stock outstanding.

This statement on Schedule 13D relates to
the common stock, $0.0001 par value per share, of Adamis Pharmaceuticals Corporation, a Delaware corporation, beneficially owned
by the Reporting Persons. The Company’s principal executive office is located at: 11682 El Camino Real, Suite 300, San Diego, CA
92130.

(a.) This Schedule 13D is being filed on behalf of (i) Eses
Holdings (FZE), a limited liability free zone establishment formed in accordance with the laws of Sharjah, United Arab Emirates
(“Eses”) and (ii) Ahmed Shayan Fazlur Rahman, a citizen of the United Kingdom (“Mr. Rahman”).
Eses is the owner of the Common Stock reported herein. Mr. Rahman controls Eses, of which he is the sole shareholder, and, accordingly,
he may be deemed to beneficially own those shares of Common Stock owned by Eses. Eses and Mr. Rahman are collectively referred
to herein as the “Reporting Persons.”

(b., c. and f.)

(i) The address of Eses’ principal place of business is
Sharjah Airport Free Zone, Executive Suite, P.O. Box 9366, Sharjah, United Arab Emirates. The principal business of Eses is to
act as a holding company. Mr. Rahman is the sole officer and director of Eses.

(ii) Mr. Rahman is a citizen of the United Kingdom, and his
present principal occupation is to act as owner and manager of Eses. Mr. Rahman’s address is c/o Eses Holdings (FZE), Sharjah
Airport Free Zone, Executive Suite, P.O. Box 9366, Sharjah, United Arab Emirates.

(d.) During the last five years, neither of the Reporting Persons
has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e.) During the last five years, neither of the Reporting Persons
has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject
to, federal or state securities laws, or finding any violation with respect to such laws.

Pursuant to the Common Stock Purchase Agreement
by and between the Company and Eses, dated November 10, 2010 (as amended, the “Stock Purchase Agreement”) the
Company issued and Eses purchased twenty million (20,000,000) shares of Common Stock on November 10, 2010. The consideration paid
by Eses for these shares of the Common Stock was five million US Dollars (US$5,000,000) in cash, which was obtained from its internal
working capital and the personal funds of Mr. Rahman.

On June 30, 2011, the Company and Eses entered
into the First Amendment to Common Stock Purchase Agreement, by and between Eses and the Company (the “First SPA Amendment”).
As previously disclosed in the Statement, the Stock Purchase Agreement obligated Eses to purchase an additional ten million (10,000,000)
shares of the Company’s Common Stock at each of two subsequent closings which were to take place after the occurrence of
specified milestones and the satisfaction of customary closing conditions. Pursuant to the First SPA Amendment, Eses agreed that
the milestones applicable to the first such milestone closing (the “First Milestone Closing”) had been met.
In addition, Eses and the Company agreed that the ten million (10,000,000) shares to be purchased at the First Milestone Closing
would be transferred in three separate installments. In connection with the first installment, which occurred on June 30, 2011,
Eses acquired two million two hundred thousand (2,200,000) shares of Common Stock in consideration for a payment of five hundred
fifty thousand US Dollars (US$550,000). In connection with the second installment, which occurred on July 21, 2011, Eses acquired
two million two hundred thousand (2,200,000) shares of Common Stock in consideration for a payment of five hundred fifty thousand
US Dollars (US$550,000). The First SPA Amendment provided that, in connection with the third installment (the “Third Installment”),
which was to occur on or before September 29, 2011, Eses would acquire an additional five million six hundred thousand (5,600,000)
shares in consideration for a payment of one million four hundred thousand US Dollars (US $1,400,000).

On November 10, 2011, the Company and Eses
entered into the Second Amendment to Common Stock Purchase Agreement (the “Second SPA Amendment”). Pursuant
to the Second SPA Amendment, the Company and Eses agreed that notwithstanding the First SPA Amendment, the five million six hundred
thousand (5,600,000) shares to be purchased in connection with the Third Installment would be transferred in two separate tranches.
In connection with the first tranche, which occurred on November 10, 2011, Eses acquired two million eight hundred thousand (2,800,000)
shares of Common Stock in consideration for a payment of seven hundred thousand US Dollars (US$700,000). In connection with the
second tranche, which was to occur on or before December 15, 2011, Eses was to acquire an additional two million eight hundred
thousand (2,800,000) shares of Common Stock in consideration for a payment of seven hundred thousand US Dollars (US$700,000).

On January 30, 2012, the Company and Eses
entered into the Third Amendment to Common Stock Purchase Agreement (the “Third SPA Amendment”). Pursuant to
the Third SPA Amendment, the Company and Eses agreed that notwithstanding the Second SPA Amendment, the two million eight hundred
thousand (2,800,000) shares of Common Stock to be purchased in connection with the second tranche of the Third Installment would
instead be transferred in three separate tranches. In connection with the first such tranche, which occurred on or about January
31, 2012, Eses acquired one million five hundred thousand (1,500,000) shares of Common Stock in consideration for a payment of
three hundred seventy-five thousand US Dollars (US$375,000). In connection with the second tranche which occurred on or about February
15, 2012, Eses acquired four hundred ninety-nine thousand six hundred eighty (499,680) shares of Common Stock in consideration
for a payment of one hundred twenty-four thousand nine hundred twenty US Dollars (US$124,920). In connection with the third tranche
which occurred on or about March 2, 2012, Eses acquired eight hundred thousand six hundred forty (800,640) shares of Common Stock
in consideration for a payment of two hundred thousand one hundred sixty US Dollars (US$200,160).

The consideration paid by Eses for the Common
Stock acquired in each of the above transactions was obtained from its internal working capital and the personal funds of Mr. Rahman.

The summary of the Stock Purchase Agreement,
First SPA Amendment, Second SPA Amendment and Third SPA Amendment contained herein does not purport to be complete and is qualified
in its entirety by the full text of each of such Agreements, which were previously filed with the SEC as exhibits to the Statement,
and are hereby incorporated herein by reference.

The Reporting Persons intend to hold the
Common Stock for investment purposes.  As discussed above in Item 3, pursuant to the Stock Purchase Agreement, as amended
by the First SPA Amendment, the Second SPA Amendment and the Third SPA Amendment, Eses acquired a total of thirty million three
hundred twenty (30,000,320) shares of Common Stock.

Under the Stock Purchase Agreement, Eses
was obligated to purchase an additional ten million (10,000,000) shares of Common Stock at the second milestone closing (the “Second
Milestone Closing”) to the extent that the applicable milestones and customary closing conditions specified in the Stock
Purchase Agreement were satisfied.  Under the Second SPA Amendment, subject to certain conditions, either party may terminate
the Stock Purchase Agreement if the milestones applicable to the Second Milestone Closing were not met by March 31, 2012 (the “outside
date”).  Prior to the Second SPA Amendment, the outside date for the Second Milestone Closing was December 31,
2011. The Second Milestone Closing was not consummated and the Company served Eses with a notice of termination of the Stock Purchase
Agreement, dated April 30, 2012.

The Reporting Persons may also acquire additional
shares of the Company’s Common Stock from time to time in open market or in privately negotiated transactions, provided such
acquisitions are on terms deemed favorable by the Reporting Persons. Alternatively, the Reporting Persons may from time to time
sell all or a portion of their shares of Common Stock in open market or in privately negotiated transactions, provided that such
sales are in compliance with applicable laws and on terms deemed favorable to the Reporting Persons.

Except as set forth herein, the Reporting
Persons have no plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities
of the Company, or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of
assets of the Company or of any of its subsidiaries; (d) any change in the present board of directors or management of the Company,
including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e)
any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company’s
business or corporate structure; (g) any change in the Company’s charter, bylaws or instruments corresponding thereto or
other action which may impede the acquisition of control of the Company by any person; (h) a class of securities of the Company
being delisted from a national securities exchange or ceasing to be authorized to be quoted in an inter-dealer quotation system
of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination
of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated in (a) through (i)
above.

(a)           The Reporting Persons beneficially
own 1,635,312 shares of Common Stock, or approximately 10.8% of the outstanding Common Stock. The shares of Common Stock beneficially
owned by the Reporting Persons are held directly by Eses. The beneficial ownership percentages reported herein are based upon the
15,077,605 shares of Common Stock outstanding as of April 11, 2016 (based on the Company’s (i) annual report on Form 10-K
filed with the SEC on March 23, 2016, indicating that 13,459,061 shares of Common Stock were outstanding as of March 23, 2016 and
(ii) current report on Form 8-K filed with the SEC on April 12, 2016, indicating that 1,618,544^§
shares of Common Stock were issued on April 11, 2016 (the “USC Closing Date”) pursuant to the Agreement and
Plan of Merger, dated as of March 28, 2016, by and among the Company, US Compounding, Inc., Ursula MergerSub Corp., and Eddie Glover,
as Stockholders’ Representative (the “Merger Agreement”).

(b)           The Reporting Persons share the power
to vote or to direct the vote and dispose or to direct the disposition of 1,635,312 shares of Common Stock.

(c)           None.

(d)           None.

(e)           Not applicable.

On November 10, 2010, the Company and Eses
entered into a Stock Purchase Agreement that has subsequently been terminated as described above in Item 4, pursuant to which Eses
purchased thirty million three hundred twenty(30,000,320) shares of the Company’s Common Stock. As described above in Items
3 and 4, on June 30, 2011, November 10, 2011 and January 30, 2012, respectively, Eses and the Company entered into the First SPA
Amendment, the Second SPA Amendment and the Third SPA Amendment, each of which amended certain provisions of the Stock Purchase
Agreement. The following represents a summary of the surviving terms of the Stock Purchase Agreement, and Registration Rights Agreement
(as defined below) that remain in effect.

Board Representation. Eses has
the right to designate a representative, reasonably satisfactory to the Company, to attend all meetings of the Board in a non-voting
observer capacity. The Company must also permit a representative of Eses to visit and inspect the Company’s offices and discuss
the Company’s affairs, finances and business with its officers. This right will terminate if: (i) Eses beneficially owns
less than 10% of the outstanding shares of Common Stock; (ii) Eses divests shares resulting in its holding fewer than twenty million
(20,000,000) shares of Common Stock; or (iii) all or substantially all of the assets of the Company are sold or a merger, consolidation
or similar transaction occurs which causes the shareholders of the Company immediately before the transaction to hold less than
a majority of the outstanding shares of the Company immediately after consummation of the transaction.

Registration Rights Agreement. The
Company and Eses have entered into a registration rights agreement, dated as of November 10, 2010 (the “Registration Rights
Agreement”). The Registration Rights Agreement was previously filed with the SEC as an exhibit to the Statement, and
is hereby incorporated herein by reference. Pursuant to the Registration Rights Agreement, the Company agreed to grant normal and
customary piggyback registration rights with respect to the shares of Common Stock purchased pursuant to the Stock Purchase Agreement.

Use of Funds. The use of the funds
received from the sale of stock pursuant to the Stock Purchase Agreement generally may only be used by the Company for the purposes
listed in Exhibit C to the Stock Purchase Agreement. The First SPA Amendment, however, provides that the proceeds of the First
Milestone Closing may also be used by the Company to pay any unconverted principal and interest due on the Company’s 10%
Senior Secured Convertible Notes.

Except as set forth in the Stock Purchase
Agreement and Registration Rights Agreement, to the best knowledge of the Reporting Persons, there exist no contracts, arrangements,
understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person
with respect to any securities of the Company, including but not limited to transfer or voting of any securities of the Company,
finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or
loss, or the giving or withholding of proxies.

SIGNATURE

After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 14, 2016